SCHEMBL5218243

SCHEMBL5218243

Oc1ccc(-c2nn(-c3c(F)cccc3Cl)c(-c3ccc(O)cc3)c2-c2ccc(O)cc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 12/20 0.39
KMT2A Q03164 4/20 0.36
MAPT P10636 3/20 0.36
LMNA P02545 2/20 0.36
TP53 P04637 2/20 0.36
MAPK1 P28482 2/20 0.36
KDM4E B2RXH2 1/20 0.36
GMNN O75496 1/20 0.36
USP2 O75604 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
ALOX12 P18054 1/20 0.36
NFKB1 P19838 1/20 0.36
CYP2C19 P33261 1/20 0.36
THPO P40225 1/20 0.36
BLM P54132 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5215737 0.96 ESR1 (0.42) ESR1KMT2AMAPTLMNATP53
SCHEMBL5214707 0.90 ESR1 (0.43) ESR1KMT2AMAPTLMNATP53
SCHEMBL5217463 0.86 ESR1 (0.46) ESR1KMT2AMAPTLMNATP53
SCHEMBL5218699 0.84 ESR1 (0.48) ESR1KMT2AMAPTLMNATP53
SCHEMBL7835517 0.78 ESR1 (0.39) ESR1KMT2AMAPTLMNATP53
SCHEMBL5216271 0.78 ESR1 (0.40) ESR1KMT2AMAPTLMNATP53
SCHEMBL5216103 0.78 CNR1 (0.45) ESR1LMNATP53
SCHEMBL5218326 0.78 KMT2A (0.39) ESR1KMT2AMAPTLMNATP53
SCHEMBL5215593 0.76 KMT2A (0.42) ESR1KMT2AMAPTLMNATP53
SCHEMBL5219898 0.76 IDO1 (0.46) ESR1KMT2AMAPTLMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE39708-E1 Estrogen receptor modulators CHIRON CORPORATION (US) 2007-06-26 US disclosed
EP-1102753-B1 PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS NOVARTIS VACCINES & DIAGNOSTIC (US) 2007-02-28 EP disclosed
US-6749674-B2 USEFUL IN RECORDING FLUIDS ESPECIALLY INK JET PRINTING PROCESSES, AND ALSO AS COLORANTS FOR ELECTROPHOTOGRAPHIC TONERS, POWDER COATINGS AND COLOR FILTERS; IMPROVED SOLUBILITY, COLORFASTNESS AND STORAGE STABILITY CLARIANT GMBH (DE) 2004-06-15 US disclosed
US-6727273-B2 THERAPY FOR OSTEOPOROSIS, ANTICANCER AGENTS CHIRON CORPORATION 2004-04-27 US disclosed
US-20040077701-A1 Estrogen receptor modulators CHIRON CORPORATION (US) 2004-04-22 US disclosed
US-20040034081-A9 ESTROGEN RECEPTOR MODULATORS CHIRON CORPORATION 2004-02-19 US disclosed
US-20020111374-A1 Estrogen receptor modulators CHIRON CORPORATION 2002-08-15 US disclosed
US-20010027734-A1 Black trisazo metal complex dyes CLARIANT GMBH 2001-10-11 US disclosed
US-6291505-B1 PYRAZOLE ESTROGEN RECEPTOR AGONIST AND ANTAGONIST CHIRON CORPORATION 2001-09-18 US disclosed
EP-1102753-A2 PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS CHIRON CORPORATION (US) 2001-05-30 EP disclosed
WO-2000007996-A2 PYRAZOLES AS ESTROGEN RECEPTOR MODULATORS CHIRON CORPORATION (US) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077701-A1 Estrogen receptor modulators ESR1, ESR2, GPER1 ESR1 1/4885KMT2A 2791/4885MAPT 1269/4885
US-20040034081-A9 ESTROGEN RECEPTOR MODULATORS ESR1, ESR2, GPER1 ESR1 1/4885KMT2A 2791/4885MAPT 1269/4885
US-20020111374-A1 Estrogen receptor modulators ESR1, ESR2, GPER1 ESR1 1/4885KMT2A 2791/4885MAPT 1269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.